Phase 1

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

Retrieved on: 
Friday, March 8, 2024

WATERTOWN, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that its preclinical data demonstrating the therapeutic potential of its potent and selective heterobifunctional degraders of STAT6 (KT-621) and TYK2 (KT-294) are being presented in the poster session at the American Academy of Dermatology’s Annual Meeting in San Diego, California. Kymera’s oral STAT6 and TYK2 degraders have the potential to address multiple immune-mediated diseases and overcome the limitations of existing technologies and agents. Today’s poster presentations mark the first time that data from a STAT6 targeted agent and a TYK2 degrader have been shared at a major medical meeting. Based on the results generated to date, Kymera intends to initiate Phase 1 testing for KT-621 and KT-294 in the in the second half of 2024 and the first half of 2025, respectively. Data from both Phase 1 trials are expected to be reported in 2025.

Key Points: 
  • Kymera’s oral STAT6 and TYK2 degraders have the potential to address multiple immune-mediated diseases and overcome the limitations of existing technologies and agents.
  • Today’s poster presentations mark the first time that data from a STAT6 targeted agent and a TYK2 degrader have been shared at a major medical meeting.
  • “Our differentiated strategy to targeted protein degradation has resulted in an industry-leading immunology pipeline of oral degrader medicines, each with the potential to treat multiple complex immuno-inflammatory diseases.
  • At low daily oral doses, preclinical studies with KT-621 demonstrated near full in vivo STAT6 degradation in disease-relevant tissues that was well-tolerated.

Alumis Announces Late-Breaker Psoriasis Phase 2 Data Presentation for Allosteric TYK2 Inhibitor ESK-001 at the American Academy of Dermatology 2024 Annual Meeting

Retrieved on: 
Monday, March 4, 2024

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced two clinical data presentations at the American Academy of Dermatology Annual Meeting taking place March 8-12, 2024, in San Diego, CA.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced two clinical data presentations at the American Academy of Dermatology Annual Meeting taking place March 8-12, 2024, in San Diego, CA.
  • Details regarding the presentations are as follows:
    Title: Efficacy and Safety of ESK-001, a Highly Selective Oral TYK2 Inhibitor, in a Phase 2 Study in
    Title: Pharmacokinetic and Pharmacodynamic Characteristics of ESK-001, an Oral Allosteric TYK2 Inhibitor, in Phase 1 Healthy Volunteer Trials
    Alumis will also host a virtual investor event to review the ESK-001 Phase 2 clinical data being presented at AAD on March 9 at 5:00 p.m. PT.
  • To access the live webcast, please register by visiting the Events page on the Alumis website.

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, February 22, 2024

Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.

Key Points: 
  • Under the terms of the Sanofi/Kymera collaboration, the dosing of the first patients generated milestone payments totaling $55 million.
  • Enrollment in both trials is ongoing, with topline data expected to be reported in the first half of 2025.
  • Kymera unveiled its first-in-class oral STAT6 degrader, KT-621, at its Immunology R&D Day in January.
  • To access the conference call via phone, please dial +1 (833) 630-2127 or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call.

Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones

Retrieved on: 
Thursday, January 4, 2024

Organizational Streamlining: Following an internal strategic review, Intellia will be streamlining company-wide operations to further focus resources on key strategic priorities and programs.

Key Points: 
  • Organizational Streamlining: Following an internal strategic review, Intellia will be streamlining company-wide operations to further focus resources on key strategic priorities and programs.
  • Cash Runway: Intellia ended the fourth quarter of 2023 with approximately $1.0 billion in cash, cash equivalents and marketable securities.
  • Prepare for the Phase 3 study of NTLA-2001 for the treatment of ATTR amyloidosis with polyneuropathy (ATTRv-PN) in 2024.
  • A live webcast will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website, www.intelliatx.com .

Pan American Energy Announces Completion of the Phase One Drilling Program at the Big Mack Lithium Project

Retrieved on: 
Wednesday, January 3, 2024

CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (CSE: PNRG | OTC: PAANF | FRA: SS60) ("Pan American” or the "Company") is pleased to announce the completion of the Phase One drilling program at the Big Mack Lithium Project (“Project”), located approximately 80 kilometers north of the town of Kenora, ON.

Key Points: 
  • CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (CSE: PNRG | OTC: PAANF | FRA: SS60) ("Pan American” or the "Company") is pleased to announce the completion of the Phase One drilling program at the Big Mack Lithium Project (“Project”), located approximately 80 kilometers north of the town of Kenora, ON.
  • The objective of the Company’s Phase One and planned Phase Two drilling programs is to quantify the presence and extent of critical mineral mineralization on the Project to further advance the Project.
  • Phase One 2023 Drilling Program Highlights:
    Big Mack Pegmatite: Drilled 19 holes (including BM 23-001) totaling 1,984 meters resulting in the extension of the known pegmatite at depth.
  • Jason Latkowcer, Chief Executive Officer, commented, “We are extremely pleased with the execution and results of our Phase One, 2023, drilling program.

Tingo Group, Inc. Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023

While there was some impact on net revenues for the second quarter, the impact was significantly greater in the third quarter due to the fact the devaluation covered the entire quarter.

Key Points: 
  • While there was some impact on net revenues for the second quarter, the impact was significantly greater in the third quarter due to the fact the devaluation covered the entire quarter.
  • The businesses of Tingo Mobile and Tingo Foods, and their respective revenues, were temporarily adversely affected during the second quarter of 2023 by the economic disruption following Nigeria’s government elections and subsequent change of presidential administrations.
  • The gross profit for the three months ended September 30, 2023, represented a decrease of $208.1 million compared to the three months ended June 30, 2023.
  • The increase is mainly attributable to the addition of the Tingo Mobile and Tingo Foods acquisitions completed on December 1, 2022, and February 9, 2023, respectively, and the commencement of export trades through Tingo DMCC in May 2023.

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

Retrieved on: 
Monday, November 13, 2023

PARIS and CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the third quarter of 2023.

Key Points: 
  • “Our robust NBTXR3 clinical program continues to demonstrate potentially transformative efficacy and well-tolerated safety across indications and patient types, including elderly and vulnerable populations.
  • Nanobiotix will host a conference call and live audio webcast on Tuesday, November 14, 2023, at 8:00 am ET / 2:00 pm CET, prior to the open of the U.S. market.
  • During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s operational progress, provide an update on business activities for the third quarter of 2023, and review the latest data presented at the 2023 Annual Congress of the European Society for Medical Oncology (ESMO), before taking questions from participants.
  • A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.

Delix Presents Interim Data From Phase I Trial of Novel Neuroplastogen at ACNP Annual Meeting

Retrieved on: 
Wednesday, December 6, 2023

Delix Therapeutics , a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders, today announced interim results from the Phase 1 trial evaluating DLX-001, a novel neuroplastogen, in healthy volunteers, which were presented at the 2023 American College of Neuropsychopharmacology (ACNP) Annual Meeting in Tampa, Florida.

Key Points: 
  • Delix Therapeutics , a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders, today announced interim results from the Phase 1 trial evaluating DLX-001, a novel neuroplastogen, in healthy volunteers, which were presented at the 2023 American College of Neuropsychopharmacology (ACNP) Annual Meeting in Tampa, Florida.
  • “Delix is excited to share these data from DLX-001, the first novel neuroplastogen to enter clinical testing.
  • These data reinforce the potential of our broader neuroplastogen platform to develop therapies that can repair damaged neurons,” said Delix CEO Mark Rus.
  • I look forward to leveraging his considerable experiences as we progress our novel neuroplastogen platform and build Delix into a leading neuroscience company."

Stratasys Partners with Siemens Healthineers in Landmark Research Project to Advance Medical Imaging

Retrieved on: 
Monday, November 27, 2023

Stratasys Ltd. (NASDAQ: SSYS), a leader in polymer 3D printing and additive manufacturing solutions, today announced it has partnered with Siemens Healthineers to carry out a landmark research project designed to develop new state-of-the-art solutions for the advancement of medical imaging phantoms for computed tomography (CT) imaging.

Key Points: 
  • Stratasys Ltd. (NASDAQ: SSYS), a leader in polymer 3D printing and additive manufacturing solutions, today announced it has partnered with Siemens Healthineers to carry out a landmark research project designed to develop new state-of-the-art solutions for the advancement of medical imaging phantoms for computed tomography (CT) imaging.
  • (Photo: Business Wire)
    A critical tool in medical imaging and an almost universal resource in hospitals worldwide, CT phantoms are specialized devices used to evaluate and ensure the performance of CT scanners.
  • “The current limitations of imaging phantoms have been a longstanding challenge for the radiology community,” said Erez Ben Zvi, Vice President Medical at Stratasys.
  • “Knowledge gained from this project provides a breakthrough in medical imaging that will open up new avenues for uses when it comes to 3D printing and imaging,” said Lampros Theodorakis, Head of Computed Tomography Product & Clinical Marketing at Siemens Healthineers.

Aspen Neuroscience to Present at Future of Parkinson's Disease Conference

Retrieved on: 
Thursday, November 30, 2023

SAN DIEGO and AUSTIN, Texas, Nov. 30, 2023 /PRNewswire/ -- This week, Aspen Neuroscience will present to the Parkinson's community at the Future of Parkinson's Disease conference, held November 30 – December 3, in Austin.

Key Points: 
  • SAN DIEGO and AUSTIN, Texas, Nov. 30, 2023 /PRNewswire/ -- This week, Aspen Neuroscience will present to the Parkinson's community at the Future of Parkinson's Disease conference, held November 30 – December 3, in Austin.
  • The joint annual conference is hosted by the Parkinson's Foundation and the Parkinson Study Group.
  • In addition to multiple scientific presentations, Aspen Chief Executive Officer Damien McDevitt, PhD, and co-founder and Senior Vice President of R&D, Andres Bratt-Leal, PhD, will present updates on company progress for upcoming Phase 1 clinical trials for ANPD001, a personalized (autologous) cell therapy under investigation to treat PD by replacing lost dopamine neurons.
  • The Aspen Neuroscience schedule of presentations includes: